Loading...
Loading...
Aldeyra Therapeutics, Inc.
ALDX (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase IIa clinical trial of NS2 for the treatment of allergic conjunctivitis.
Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, "With the first patient enrolled in our allergic conjunctivitis Phase IIa trial, we are now actively studying NS2 in three indications. Over the past year, we have made tremendous progress in expanding the clinical development of NS2, adding to the number of opportunities to demonstrate the potential of our novel therapeutic in the treatment of diseases thought to be mediated by aldehydes."
A synopsis of the trial is expected to be available on www.clinicaltrials.gov within 21 days.
About NS2
NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate excessive inflammation and address diseases where aldehydes are thought to mediate pathology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in